Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials

Hongxing Pan, Jiankai Liu, Baoying Huang, Guifan Li, Xianyun Chang, Yafei Liu, Wenling Wang, Kai Chu, Jialei Hu, Jingxin Li, Dandan Zhu, Jingliang Wu, Xiaoyu Xu, Li Zhang, Meng Wang, Wenjie Tan, Weijin Huang, Fengcai Zhu
doi: https://doi.org/10.1101/2021.04.07.21253850
Hongxing Pan
1NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China or at
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tanwj{at}ivdc.chinacdc.cn
Jiankai Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baoying Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guifan Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xianyun Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yafei Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenling Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Chu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jialei Hu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingxin Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dandan Zhu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingliang Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyu Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meng Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenjie Tan
1NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China or at
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tanwj{at}ivdc.chinacdc.cn huangweijin{at}nifdc.org.cn jszfc{at}vip.sina.com tanwj{at}ivdc.chinacdc.cn
Weijin Huang
2China National Institute for Food and Drug Control, Beijing, 102206, China or at
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tanwj{at}ivdc.chinacdc.cn huangweijin{at}nifdc.org.cn jszfc{at}vip.sina.com huangweijin{at}nifdc.org.cn
Fengcai Zhu
3Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009, China or at
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tanwj{at}ivdc.chinacdc.cn huangweijin{at}nifdc.org.cn jszfc{at}vip.sina.com jszfc{at}vip.sina.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults.

Methods Two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in Chinese healthy adults aged 18 through 59 years. The phase 1 trial was conducted in a manner of dosage escalation. The first 30 participants were randomized in a ratio of 4:1 to receive two doses of either KCONVAC at 5 μg per dose or placebo on Day 0 and Day 14, and the second 30 participants were randomized to receive either KCONVAC at 10 μg per dose or placebo following the same procedures. The participants in the phase 2 trial were randomized in a ratio of 2:2:1 to receive either KCONVAC at 5 μg or 10 μg per dose, or placebo on Day 0 and Day 14, or Day 0 and Day 28. In the phase 1 trial, the primary safety endpoint was the proportion of participants experiencing adverse reactions/events within 28 days following each vaccination. Antibody response and cellular response were assayed in the phase 1 trial. In the phase 2 trial, the primary immunogenicity endpoint was the seroconversion and titre of neutralization antibody, and the seroconversion of receptor binding domain (RBD)-IgG 28 days after the second dose.

Findings In the phase 1 trial, 60 participants were enrolled and received at least one dose of 5-μg vaccine (N=24), 10-μg vaccine (N=24), or placebo (N=12). In the phase 2 trial, 500 participants were enrolled and received at least one dose of 5-μg vaccine (N=100 for 0/14 or 0/28 regimens), 10-μg vaccine (N=100 for each regimen), or placebo (N=50 for each regimen). In the phase 1 trial, 13 (54%), 11(46%), and 7 (58%) participants reported at least one adverse event (AE), of whom 10 (42%), 6 (25%), and 6 (50%) participants reported at least one vaccination-related AE after receiving 5-μg vaccine, 10-μg vaccine, or placebo, respectively. In the phase 2 trial, 16 (16%), 19 (19%), and 9 (18%) participants reported at least one AE, of whom 13 (13%), 17 (17%), and 6 (12%) participants reported at least one vaccination-related AE after receiving 5-μg vaccine, 10-μg vaccine, or placebo at the regimen of Day 0/14, respectively. Similar results were observed in the three treatment groups of Day 0/28 regimen. All the AEs were grade 1 or 2 in intensity. No AE of grade 3 or more was reported. One SAE (foot fracture) was reported in the phase 1 trial. KCONVAC induced significant antibody response. 87·5% (21/24) to 100% (24/24) of participants in the phase 1 trial and 83·0% (83/100) to 100% (99/99) of participants in the phase 2 trial seroconverted for neutralising antibody to live virus, neutralising antibody to pseudovirus, and RBD-IgG after receiving two doses. Across the treatment groups in the two trials, the geometric mean titres (GMTs) of neutralising antibody to live virus ranged from 29·3 to 49·1 at Day 0/14 regimen and from 100·2 to 131·7 at Day 0/28 regimen, neutralising antibody to pseudovirus ranged from 69·4 to 118·7 at Day 0/14 regimen and from 153·6 to 276·6 at Day 0/28 regimen, and RBD-IgG ranged from 605·3 to 1169·8 at Day 0/14 regimen and from 1496·8 to 2485·5 at Day 0/28 regimen. RBD-IgG subtyping assay showed that a significant part of RBD-IgG was IgG1. The vaccine induced obvious T-cell response with 56·5% (13/23) and 62·5% (15/24) of participants in 5-μg and 10-μg vaccine groups showed positive interferon-γ enzyme-linked immunospot responses 14 days after the second dose in the phase 1 trial, respectively.

Interpretation KCONVAC is well tolerated and able to induce robust antibody response and cellular response in adults aged 18 to 59 years, which warrants further evaluation with this vaccine in the upcoming phase 3 efficacy trial.

Funding Guandong Emergency Program for Prevention and Control of COVID-19 (2020A1111340002) and Shenzhen Key Research Project for Prevention and Control of COVID-19.

Competing Interest Statement

JianL is an employee of Shenzhen Kangtai Biological Products. GL, XC, and YL are employees of Beijing Minhai Biotechnology. All other authors declare no competing interests.

Clinical Trial

The studies were registered with ClinicalTrials.gov, number NCT04758273 and NCT04756323.

Funding Statement

Guandong Emergency Program for Prevention and Control of COVID-19 (2020A1111340002) and Shenzhen Key Research Project for Prevention and Control of COVID-19.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies were done in accordance with the Declaration of Helsinki and Good Clinical Practice. An independent data safety monitoring board was established before the start of the trials to provide oversight of the safety data during the studies. The protocols and informed consents were approved by the institutional review board of JPCDC.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Supporting clinical documents including study protocol and statistical analysis plan will be available immediately following publication for at least 1 year. Researchers who provide a scientifically sound proposal will be allowed access to the individual participant data. Proposals should be directed to jszfc{at}vip.sina.com. These proposals will be reviewed and approved by the funder, investigator, and collaborators on the basis of scientific merit. To gain access, data requesters will need to sign a data access agreement.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
Hongxing Pan, Jiankai Liu, Baoying Huang, Guifan Li, Xianyun Chang, Yafei Liu, Wenling Wang, Kai Chu, Jialei Hu, Jingxin Li, Dandan Zhu, Jingliang Wu, Xiaoyu Xu, Li Zhang, Meng Wang, Wenjie Tan, Weijin Huang, Fengcai Zhu
medRxiv 2021.04.07.21253850; doi: https://doi.org/10.1101/2021.04.07.21253850
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
Hongxing Pan, Jiankai Liu, Baoying Huang, Guifan Li, Xianyun Chang, Yafei Liu, Wenling Wang, Kai Chu, Jialei Hu, Jingxin Li, Dandan Zhu, Jingliang Wu, Xiaoyu Xu, Li Zhang, Meng Wang, Wenjie Tan, Weijin Huang, Fengcai Zhu
medRxiv 2021.04.07.21253850; doi: https://doi.org/10.1101/2021.04.07.21253850

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (754)
  • Anesthesia (221)
  • Cardiovascular Medicine (3286)
  • Dentistry and Oral Medicine (363)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13352)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5142)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3263)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1016)
  • Infectious Diseases (except HIV/AIDS) (14618)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4916)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2518)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4201)
  • Public and Global Health (7492)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (204)